Acronyms that contain the term supernus pharmaceuticals  Page #5

Supernus Pharmaceuticals

Headquartered in Rockville, MD, Supernus Pharmaceuticals, Inc. (formerly Shire Laboratories) is a specialty pharmaceuticals company that has a broad portfolio of proven and patented drug delivery technologies. Among its key technologies are ProScreen® and OptiScreen® for lead selection and formulation optimization, Microtrol®, Solutrol® and EnSoTrol®, its oral controlled release technologies, and AvertSM, its reduced abuse potential technology. Supernus will focus on developing differentiated products for targeted specialty therapeutic areas on its own and in partnership with other pharmaceutical companies. The company's portfolio of technologies covers the areas of: Predictive oral bioavailability evaluation using ProScreen®, ProPhile® and RADARSM Oral bioavailability enhancement including solubility enhancement, permeation enhancement, and efflux and protease protection. The OptiScreen® technology platform is designed to select enhancers and build novel formulations (ie: Emutrol™ to enhance oral bioavailability Oral controlled release including Microtrol®XR, Microtrol®PR, Microtrol®DR, Solutrol®, and EnSoTrol®, all of which are proven and patented technologies Reduced abuse potential via application of Avert for products containing DEA scheduled substances The pharmaceutical marketplace continually reinforces its preference for the convenience of orally administered products. In fact, over 70% of all pharmaceutical products are administered via the oral route. The advent of high throughput discovery techniques has taken drug discovery to new heights and has increased the number of drug candidates but has done little to address the inherent need for candidates to be orally administered. Supernus' ProScreen®, ProPhile®, RADARSM and OptiScreen® programs are comprised of proprietary techniques for identifying and overcoming potential barriers to oral administration. This enables development of promising candidates that may otherwise be abandoned and optimization of delivery for known entities. ProScreen® is a predictive screen for candidates that warrant oral delivery; ProPhile® is a suite of in silico modeling tools that enables multivariate analysis and PK prediction; and OptiScreen® is a technology for formulation optimization leading to oral bioavailability enhancement. Many candidates also require customized release profiles in order to more effectively address the indication of interest or minimize unwanted side effects that may be related to Cmax or patient to patient variability. Supernus possesses an array of proven and patented controlled release technology platforms to address the specific need of the molecule. More specifically, Microtrol®XR, Microtrol®PR, Microtrol®DR, Solutrol®, and EnSoTrol® provide Supernus’ partners access to technologies in the three technological categories for oral controlled release. The broad based array of technologies makes Supernus Pharmaceuticals the leader in oral controlled release while also maximizing its partners’ chance of success. RADARSM is a platform recently launched by Supernus Pharmaceuticals that compliments its existing technology platforms. When evaluating whether a molecule is a viable candidate for oral controlled release it is important to know the degree to which it is absorbed along the entire length of the gastrointestinal tract. A significant number of compounds possess divergent absorption profiles in various segments of the gastrointestinal tract, thus increasing the complexity or completely precluding development of a controlled or extended release dosage form. It is of substantial value to determine relative bioavailability of a molecule by region of the gastrointestinal tract before initiating a fully integrated development program for a controlled or extended release dosage form. Supernus created AvertSM and RADARSM as a platform to reduce abuse...

see more »